DK2451452T3 - Anvendelse af benzydamin ved behandling af p40-afhængige sygdomme - Google Patents
Anvendelse af benzydamin ved behandling af p40-afhængige sygdomme Download PDFInfo
- Publication number
- DK2451452T3 DK2451452T3 DK10728191.7T DK10728191T DK2451452T3 DK 2451452 T3 DK2451452 T3 DK 2451452T3 DK 10728191 T DK10728191 T DK 10728191T DK 2451452 T3 DK2451452 T3 DK 2451452T3
- Authority
- DK
- Denmark
- Prior art keywords
- acid
- benzydamine
- physiologically acceptable
- addition salts
- expressed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (11)
1. Anvendelse af benzydamin eller de fysiologisk acceptable syreadditionssalte deraf ved fremstilling af et medikament til behandling af en inflammationssygdom forårsaget af eksprimering af cytokin-underenhed p40, hvori inflammationssygdommen er valgt fra gruppen bestående af Crohns sygdom, psoriatisk artritis og psoriasis.
2. Anvendelse ifølge krav 1, hvori medikamentet er formuleret til systemisk eller topisk indgivelse.
3. Anvendelse ifølge krav 2, hvori medikamentet til systemisk indgivelse omfatter en mængde fra 1 mg til 100 mg, mere foretrukket fra 5 mg til 50 mg, benzydamin eller de fysiologisk acceptable syreadditionssalte deraf, udtrykt som fri base.
4. Anvendelse ifølge krav 2, hvori medikamentet til topisk indgivelse omfatter en mængde fra 1 til 20 vægt-%, mere foretrukket fra 1 til 10 vægt-%, benzydamin eller de fysiologisk acceptable syreadditionssalte deraf, udtrykt som fri base, baseret på medikamentets samlede vægt.
5. Anvendelse ifølge krav 2, hvori medikamentet gives i en daglig dosis fra 50 mg/kg til 0,1 mg/kg benzydamin eller de fysiologisk acceptable syreadditionssalte deraf, udtrykt som fri base.
6. Anvendelse ifølge krav 2, hvori medikamentet til systemisk indgivelse gives som en daglig dosis fra 5 mg/kg til 0,1 mg/kg benzydamin eller de fysiologisk acceptable syreadditionssalte deraf, udtrykt som fri base.
7. Anvendelse ifølge krav 2, hvori medikamentet til topisk indgivelse gives som en daglig dosis fra 50 mg/kg til 1 mg/kg benzydamin eller de fysiologisk acceptable syreadditionssalte deraf, udtrykt som fri base.
8. Farmaceutisk sammensætning til anvendelse ved behandling af en inflammatorisk sygdom forårsaget ved eksprimering af cytokin-underenhed p40 ved systemisk eller topisk indgivelse, hvori inflammationssygdommen er valgt fra gruppen bestående af Crohns sygdom, psoriatisk artritis og psoriasis, hvori den farmaceutiske sammensætning omfatter benzydamin eller de fysiologisk acceptable syreadditionssalte deraf.
9. Farmaceutisk sammensætning ifølge anvendelsen ifølge krav 8, hvori den farmaceutiske sammensætning omfatter en mængde fra 1 mg til 100 mg, mere foretrukket fra 5 mg til 50 mg, benzydamin eller de fysiologisk acceptable syreadditionssalte deraf, udtrykt som fri base, hvori sammensætningen er til systemisk indgivelse.
10. Farmaceutisk sammensætning ifølge anvendelsen ifølge krav 8, hvori den farmaceutiske sammensætning omfatter en mængde fra 1 til 20 vægt-%, mere foretrukket fra 1 til 10 vægt-%, benzydamin eller de fysiologisk acceptable syreadditionssalte deraf, udtrykt som fri base, baseret på medikamentets samlede vægt, hvori sammensætningen er til topisk indgivelse.
11. Farmaceutisk sammensætning ifølge anvendelsen ifølge ethvert af krav 8 til 10, hvori det fysiologisk acceptable syreadditionssalt af benzydamin er fremskaffet med en uorganisk eller organisk syre valgt fra gruppen omfattende saltsyre, bromsyre, svovlsyre, fosforsyre, salpetersyre, eddikesyre, askorbinsyre, benzoesyre, citronsyre, fumarsyre, mælkesyre, maleinsyre, metansulfonsyre, oxalsyre, paratoluensulfonsyre, benzensulfonsyre, ravsyre, garvesyre og vinsyre, hvori sammensætningen er til systemisk eller topisk indgivelse.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09425270 | 2009-07-08 | ||
| PCT/EP2010/058881 WO2011003737A1 (en) | 2009-07-08 | 2010-06-23 | USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2451452T3 true DK2451452T3 (da) | 2015-11-23 |
Family
ID=41279454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10728191.7T DK2451452T3 (da) | 2009-07-08 | 2010-06-23 | Anvendelse af benzydamin ved behandling af p40-afhængige sygdomme |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20120302618A1 (da) |
| EP (1) | EP2451452B1 (da) |
| JP (1) | JP5753843B2 (da) |
| KR (1) | KR101723996B1 (da) |
| CN (1) | CN102470125B (da) |
| AR (1) | AR077451A1 (da) |
| AU (1) | AU2010270425B2 (da) |
| BR (1) | BR112012000410B8 (da) |
| CA (1) | CA2760176C (da) |
| CY (1) | CY1116914T1 (da) |
| DK (1) | DK2451452T3 (da) |
| EA (1) | EA022862B1 (da) |
| ES (1) | ES2554332T3 (da) |
| GE (1) | GEP20146156B (da) |
| HK (1) | HK1165280A1 (da) |
| HR (1) | HRP20151393T8 (da) |
| HU (1) | HUE028220T2 (da) |
| IL (1) | IL216717A (da) |
| MX (1) | MX2012000498A (da) |
| PL (1) | PL2451452T3 (da) |
| PT (1) | PT2451452E (da) |
| SG (2) | SG176686A1 (da) |
| SI (1) | SI2451452T1 (da) |
| SM (1) | SMT201500277B (da) |
| UA (1) | UA105666C2 (da) |
| WO (1) | WO2011003737A1 (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201906474QA (en) * | 2015-02-09 | 2019-09-27 | Cellix Bio Private Ltd | Compositions and methods for the treatment of mucositis |
| WO2017044752A1 (en) * | 2015-09-10 | 2017-03-16 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Anti-fibrotic effect of cd70 |
| WO2018007288A1 (en) * | 2016-07-08 | 2018-01-11 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Pharmaceutical composition comprising benzydamine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1054833A (da) | 1963-08-09 | |||
| IT1184123B (it) | 1985-01-22 | 1987-10-22 | Acraf | Impiego della benzidamina nel trattamento delle infezioni da trichomonas vaginalis e gardnerella vaginalis |
| IT1276040B1 (it) * | 1993-07-27 | 1997-10-24 | Angelini Francesco Ist Ricerca | Uso della benzidamina nel trattamento di stati patologici causati dal tnf |
| IT1274026B (it) | 1994-03-01 | 1997-07-14 | Acraf | Composizione antitosse |
| IT1274655B (it) * | 1995-02-28 | 1997-07-18 | Smithkline Beecham Farma | Composizioni farmaceutiche contenenti un agente antiinfiammatorio e un agente antimicrobico |
| CA2594718C (en) * | 2005-01-14 | 2012-01-24 | Camurus Ab | Gnrh analogue formulations |
| US8920782B2 (en) * | 2005-01-14 | 2014-12-30 | Camurus Ab | Topical bioadhesive formulations |
| GB0604824D0 (en) * | 2006-03-09 | 2006-04-19 | Arakis Ltd | The treatment of inflammatory disorders |
-
2010
- 2010-06-23 AU AU2010270425A patent/AU2010270425B2/en not_active Ceased
- 2010-06-23 EA EA201270143A patent/EA022862B1/ru unknown
- 2010-06-23 JP JP2012518870A patent/JP5753843B2/ja active Active
- 2010-06-23 BR BR112012000410A patent/BR112012000410B8/pt not_active IP Right Cessation
- 2010-06-23 CN CN201080028333.5A patent/CN102470125B/zh not_active Expired - Fee Related
- 2010-06-23 CA CA2760176A patent/CA2760176C/en not_active Expired - Fee Related
- 2010-06-23 MX MX2012000498A patent/MX2012000498A/es unknown
- 2010-06-23 WO PCT/EP2010/058881 patent/WO2011003737A1/en active Application Filing
- 2010-06-23 HU HUE10728191A patent/HUE028220T2/en unknown
- 2010-06-23 PL PL10728191T patent/PL2451452T3/pl unknown
- 2010-06-23 SG SG2011090032A patent/SG176686A1/en unknown
- 2010-06-23 UA UAA201200082A patent/UA105666C2/uk unknown
- 2010-06-23 EP EP10728191.7A patent/EP2451452B1/en active Active
- 2010-06-23 GE GEAP201012558A patent/GEP20146156B/en unknown
- 2010-06-23 DK DK10728191.7T patent/DK2451452T3/da active
- 2010-06-23 ES ES10728191.7T patent/ES2554332T3/es active Active
- 2010-06-23 PT PT107281917T patent/PT2451452E/pt unknown
- 2010-06-23 SG SG10201403088XA patent/SG10201403088XA/en unknown
- 2010-06-23 KR KR1020117031281A patent/KR101723996B1/ko active IP Right Grant
- 2010-06-23 SI SI201031052T patent/SI2451452T1/sl unknown
- 2010-06-23 US US13/382,450 patent/US20120302618A1/en not_active Abandoned
- 2010-07-06 AR ARP100102406A patent/AR077451A1/es not_active Application Discontinuation
-
2011
- 2011-12-01 IL IL216717A patent/IL216717A/en active IP Right Grant
-
2012
- 2012-06-18 HK HK12105915.7A patent/HK1165280A1/zh not_active IP Right Cessation
-
2015
- 2015-11-06 SM SM201500277T patent/SMT201500277B/it unknown
- 2015-11-13 CY CY20151101024T patent/CY1116914T1/el unknown
- 2015-12-18 HR HRP20151393TT patent/HRP20151393T8/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI280136B (en) | Composition containing dipeptide of histidine and alanine for reducing uric acid | |
| WO2021135654A1 (zh) | 双硫仑在制备防治nlrp3炎症小体相关疾病的药物中的应用 | |
| AU2007280625B2 (en) | Use of escin | |
| DK2451452T3 (da) | Anvendelse af benzydamin ved behandling af p40-afhængige sygdomme | |
| CN116983417A (zh) | IRE1α抑制剂在制备治疗多发性硬化症药物中的应用 | |
| WO2018175334A1 (en) | Compositions and methods for skin treatments | |
| Mahajan et al. | Recent Updates on Psoriasis: A Review | |
| TWI435727B (zh) | 調節細胞激素分泌之用途 | |
| JP2021510159A (ja) | セルドゥラチニブ含有局所皮膚医薬組成物およびその使用 | |
| CN112245422B (zh) | 乙酰缬草素的新应用 | |
| JP7290223B2 (ja) | ＩＬ－１β阻害薬 | |
| JP5575927B2 (ja) | ペントキシフィリンの便秘の予防または治療における応用 | |
| TW471967B (en) | Use of 6,7-substituted-2-aminotetralines for preparing pharmaceutical compositions useful for the treatment of septic shock, and antipyretic and antiinflammatory pharmaceutical compositions | |
| EP3323416B1 (en) | Pharmaceutical composition for treating premature ejaculation | |
| WO2022222948A1 (zh) | 包含jak3/jak1/tbk1选择性抑制剂的药物组合物及其医药用途 | |
| JP2004182638A (ja) | 炎症性疾患又は悪性腫瘍の予防治療剤 | |
| RU2192250C2 (ru) | Способ лечения больных красным плоским лишаем | |
| JP2010047518A (ja) | 鼻閉抑制剤 | |
| WO2023203022A1 (en) | Treatment of neutrophilic dermatoses | |
| Elsaied et al. | TNF-α localization in the Dental Pulp of Albino Rats Receiving Long Term Treatment with Tramadol Hydrochloride | |
| TW202135816A (zh) | 以激酶抑制劑治療潰瘍性結腸炎 | |
| Smirnova et al. | An Integrated Approach to the Treatment of Severe Psoriasis: A Clinical Case | |
| KR20210008899A (ko) | 메트포민을 유효성분으로 포함하는 피부질환 예방 또는 치료용 약학적 조성물 | |
| CN117897151A (zh) | 用于治疗帕金森氏病的方法 | |
| CN113230255A (zh) | 阿帕替尼在制备防治nlrp3炎症小体相关疾病的药物中的应用 |